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Editorial
Vascular biology: New mechanisms and pathways
Vascular biology is at the forefront of basic and translational research
due to its interdisciplinary signiﬁcance. The interest in the mechanisms
of blood vessel formation, physiology and pathology of the cardiovascu-
lar system is exempliﬁed by the countless number of publications
appearing every year. Therefore, one can imagine the difﬁculties in
selecting the most important subjects to present in a single journal
issue; every choice has its limitations.
The current special issue of Vascular Pharmacology is such a selection
of papers prepared on the basis of presentations delivered during
the joint meeting of the European Vascular Biology Organisation and
the European Society for Microcirculation, held in Pisa, Italy, from
June 3 to 6th, 2015. This was the ﬁrst joint conference of both societies,
and corresponded to the 28th ESM and 8th EVBO meeting.
More than a year has passed since that unforgettable time in the
beautiful Tuscan city of Pisa; therefore many of the results presented
during the meeting have been published already in the form of original
research papers in numerous journals. However, EVBO also chose to
prepare a special issue of Vascular Pharmacology, to summarise, mostly
in the form of review papers, selected topics discussed during the
meeting. This special issue is the second association between EVBO and
Vascular Pharmacology, the ﬁrst one published after the 6th EVBO
Meeting (Krakow, 21–24 September 2011) [1,2]. This issue is of particu-
lar signiﬁcance, as Vascular Pharmacology is currently the EVBO ofﬁcial
journal, a decision thatwas ratiﬁed at the AGMheld during Pisameeting.
In this special issue, the ﬁrst two reviews concern basic aspects of
vascular development and angiogenesis. The molecular mechanisms
that control endothelial homeostasis, vascular development and angio-
genesis, and the role of the transcription factor ERG in these processes,
are discussed by Shah and co-workers [3]. A brief update on the VEGF
receptor signal transduction pathways, crucial tomultiple aspects of en-
dothelial biology, is delivered by Lena Claesson-Welsh [4], the plenary
speaker who closed the Pisa meeting. The role of VEGF in limb ischemia
and vessel regeneration is discussed by Jazwa et al. in a review [5] ad-
dressing the subject with a new perspective, calling into the question
the role of this protein in experimental and clinical limb ischemia.
Inﬂammation is the critical event in the pathogenesis of vascular
disease. In this context the role of cytochrome P450-derived lipid
mediators in physiological and pathological vascular signalling is
discussed by Ingrid Fleming [6]. Next the cytoprotective pathways in
the endothelium, with particular relevance to atherogenesis, are exten-
sively elucidated by Justin Mason [7]. Both those reviews focus mainly
on the endothelium. However, maturation and proper functioning of
blood vessels is also dependent on mural cells. Microvascular pericytes
control angiogenesis, blood ﬂow and vascular permeability. The review
by Avolio and Madeddu [8] concentrates on elucidating the origin of
those cells, their pathophysiological mechanisms, the understanding
of which is crucial for the potential therapeutic applications in ischemic
heart diseases.
Communication between vascular cells is executed by innumerable
mediators. The mode of communications can be variable; in recent
years particular interest has focussed on extracellular vesicles (ECVs).
Some of these ECVs can be released as the result of cell death
(apoptosis), while those involved in active exchange of information be-
tween the cells are usually classiﬁed as smaller exosomes (40–100 nm
in diameter) and larger microparticles (0.1–1 μM). The role of extracel-
lular vesicles as a newplayer of angiogenesis is discussed byKholia et al.
[9], while McCarthy et al. present their views on the pathogenic or
passive role of endothelial microparticles in endothelial dysfunction in
autoimmune rheumatic diseases [10]
The pathological changes in the vessel wall can lead to vascular
calciﬁcation, a topic not often discussed at vascular biology meetings.
The EVBO special issue fulﬁls this need by providing a comprehensive
review and an original paper. An overview of numerous mechanisms
underpinning vascular calciﬁcation and the links with bone loss in a
bi-directional interplay is presented by Cristina Vassalle and Annamaria
Mazzone [11]. In their research paper, Zhu et al. [12] discuss the novel
role for mineralocorticoid receptor in glucocorticoid-driven vascular
calciﬁcation, and the evidence for their role in calciﬁcation of vascular
smooth muscle cells.
The ﬁnal paper in the special issue is an original study by
Kachamakova-Trojanowska et al. [13] in which the angiogenic capacity
of functional murine iPSC-derived ECs are directly compared to bone
marrow derivedmesenchymal stromal cells (MSCs), which are claimed
to possess similar features. The study demonstrates that, in contrast
to iPSC-derived ECs, murine MSCs do not reveal efﬁcient blood vessel-
forming capacities.
Asmentioned, any selectionwill inevitably leave out deserving topics.
Despite being aware of insightful omissions, we however believe that the
papers collected in this issue may generate new ideas for the readers
and remind the participants of the conference of the hot scientiﬁc (and
otherwise!) atmosphere of the Pisameeting. For thosewhodidnot attend
the meeting, this themed issue aims at providing an overview of several
topical subjects which are the focus of exciting new research, at elucidat-
ing existing doubts and at ﬁlling the gaps in our knowledge. We propose
that this special issue could also be the seed for a similar one to follow the
upcoming next joint meeting of EVBO and ESM (http://esm-evbo2017.
org/), to be held in Geneva, Switzerland, from 29th May to 1st June in
2017. We look forward to seeing you all there to share our interest and
enthusiasm for vascular biology research.
Jozef Dulak – President of EVBO.
Yvonne Alexander – EVBO councillor.
Anna Randi – Secretary of EVBO.
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